User login
Highlights From ECTRIMS 2018
Expert Opinions: Considerations to Guide Conversion From Carbamazepine or Oxcarbazepine to Eslicarbazepine Acetate
Patients typically switch from carbamazepine (CBZ) or oxcarbazepine (OXC) to eslicarbazepine acetate (ESL) for at least 1 of 3 reasons: tolerability, simpler dosing, and/or efficacy. Since no evidence-based recommendations exist regarding the switching schedule, expert opinions may prove helpful for practitioners. In this supplement, expert epileptologists and clinical trialists share their experience about switching patients from CBZ or OXC to ESL.
Supplement
Click here or on the image below to read the supplement
Podcasts
Dr. Elinor Ben-Menachem discusses the case of a 28-year-old man with focal onset epilepsy who was switched from CBZ to ESL.
Dr. Toufic Fakhoury discusses the case of a 34-year-old female who became seizure-free after switching from OXC to ESL.
Dr. Mohamad Koubeissi discusses the case of a 22-year-old man with intractable epilepsy who was switched from OXC to ESL.
Dr. John Stern discusses the case of a 48-year-woman with tonic-clonic seizures who was switched from CBZ to ESL.
Dr. James Wheless discusses the case of an 8-year-old male who found relief having switched from OXC to ESL.
About the Faculty
Professor of Neurology
Director, Epilepsy Center
George Washington University
Washington, DC
Professor
Institute of Neuroscience and Physiology
Department of Clinical Neurosciences
The Sahlgrenska Academy at the University of Gothenburg
Department of Neurology
Sahlgrenska University Hospital
Gothenburg, Sweden
Saint Joseph Health System
Lexington, KY
Professor, Department of Neurology
Director, Epilepsy Clinical Program
Director, Epilepsy Residency Training Program
David Geffen School of Medicine
University of California, Los Angeles
Los Angeles, CA
Professor and Chief, Department of Pediatric Neurology
Chair, Division of Pediatric Neurology
Director, Le Bonheur Comprehensive Epilepsy Program
Director, Le Bonheur Neuroscience Center
University of Tennessee Health Science Center
Memphis, TN
Patients typically switch from carbamazepine (CBZ) or oxcarbazepine (OXC) to eslicarbazepine acetate (ESL) for at least 1 of 3 reasons: tolerability, simpler dosing, and/or efficacy. Since no evidence-based recommendations exist regarding the switching schedule, expert opinions may prove helpful for practitioners. In this supplement, expert epileptologists and clinical trialists share their experience about switching patients from CBZ or OXC to ESL.
Supplement
Click here or on the image below to read the supplement
Podcasts
Dr. Elinor Ben-Menachem discusses the case of a 28-year-old man with focal onset epilepsy who was switched from CBZ to ESL.
Dr. Toufic Fakhoury discusses the case of a 34-year-old female who became seizure-free after switching from OXC to ESL.
Dr. Mohamad Koubeissi discusses the case of a 22-year-old man with intractable epilepsy who was switched from OXC to ESL.
Dr. John Stern discusses the case of a 48-year-woman with tonic-clonic seizures who was switched from CBZ to ESL.
Dr. James Wheless discusses the case of an 8-year-old male who found relief having switched from OXC to ESL.
About the Faculty
Professor of Neurology
Director, Epilepsy Center
George Washington University
Washington, DC
Professor
Institute of Neuroscience and Physiology
Department of Clinical Neurosciences
The Sahlgrenska Academy at the University of Gothenburg
Department of Neurology
Sahlgrenska University Hospital
Gothenburg, Sweden
Saint Joseph Health System
Lexington, KY
Professor, Department of Neurology
Director, Epilepsy Clinical Program
Director, Epilepsy Residency Training Program
David Geffen School of Medicine
University of California, Los Angeles
Los Angeles, CA
Professor and Chief, Department of Pediatric Neurology
Chair, Division of Pediatric Neurology
Director, Le Bonheur Comprehensive Epilepsy Program
Director, Le Bonheur Neuroscience Center
University of Tennessee Health Science Center
Memphis, TN
Patients typically switch from carbamazepine (CBZ) or oxcarbazepine (OXC) to eslicarbazepine acetate (ESL) for at least 1 of 3 reasons: tolerability, simpler dosing, and/or efficacy. Since no evidence-based recommendations exist regarding the switching schedule, expert opinions may prove helpful for practitioners. In this supplement, expert epileptologists and clinical trialists share their experience about switching patients from CBZ or OXC to ESL.
Supplement
Click here or on the image below to read the supplement
Podcasts
Dr. Elinor Ben-Menachem discusses the case of a 28-year-old man with focal onset epilepsy who was switched from CBZ to ESL.
Dr. Toufic Fakhoury discusses the case of a 34-year-old female who became seizure-free after switching from OXC to ESL.
Dr. Mohamad Koubeissi discusses the case of a 22-year-old man with intractable epilepsy who was switched from OXC to ESL.
Dr. John Stern discusses the case of a 48-year-woman with tonic-clonic seizures who was switched from CBZ to ESL.
Dr. James Wheless discusses the case of an 8-year-old male who found relief having switched from OXC to ESL.
About the Faculty
Professor of Neurology
Director, Epilepsy Center
George Washington University
Washington, DC
Professor
Institute of Neuroscience and Physiology
Department of Clinical Neurosciences
The Sahlgrenska Academy at the University of Gothenburg
Department of Neurology
Sahlgrenska University Hospital
Gothenburg, Sweden
Saint Joseph Health System
Lexington, KY
Professor, Department of Neurology
Director, Epilepsy Clinical Program
Director, Epilepsy Residency Training Program
David Geffen School of Medicine
University of California, Los Angeles
Los Angeles, CA
Professor and Chief, Department of Pediatric Neurology
Chair, Division of Pediatric Neurology
Director, Le Bonheur Comprehensive Epilepsy Program
Director, Le Bonheur Neuroscience Center
University of Tennessee Health Science Center
Memphis, TN
COPD and Asthma Supplement
COPD and Asthma Update
"COPD and Asthma Update" is a clinical aid for PCPs to further understand and manage patients with COPD or asthma. Click here to read the supplement, then click the buttons below for supplementary materials to each chapter.
Supplementary Materials:
COPD and Asthma Update
"COPD and Asthma Update" is a clinical aid for PCPs to further understand and manage patients with COPD or asthma. Click here to read the supplement, then click the buttons below for supplementary materials to each chapter.
Supplementary Materials:
COPD and Asthma Update
"COPD and Asthma Update" is a clinical aid for PCPs to further understand and manage patients with COPD or asthma. Click here to read the supplement, then click the buttons below for supplementary materials to each chapter.
Supplementary Materials:
Pediatric Vaccines & Infectious Diseases: Fall 2018
Psoriasis & Psoriatic Arthritis - October 2018 Supplement
Psoriasis & Psoriatic Arthritis is a supplement addressing new therapeutic advances and research that will change patient care. “We highlight late-breaking, novel research that will help shape the future of psoriasis therapeutics. Specifically, we discuss psoriasis research that has focused on traditionally overlooked subpopulations,” noted Dr. April W. Armstrong in the supplement’s introduction. Dr. Alan Menter added, “With the introduction of new interleukin (IL)-17 as well as IL-23 biologic drugs for the treatment of moderate to severe psoriasis, as well as IL-17 and IL-23 drugs in the pipeline, we in the field of psoriasis will have an excellent group of quality bio- logic drugs available to us within the next year.
Psoriasis & Psoriatic Arthritis is a supplement addressing new therapeutic advances and research that will change patient care. “We highlight late-breaking, novel research that will help shape the future of psoriasis therapeutics. Specifically, we discuss psoriasis research that has focused on traditionally overlooked subpopulations,” noted Dr. April W. Armstrong in the supplement’s introduction. Dr. Alan Menter added, “With the introduction of new interleukin (IL)-17 as well as IL-23 biologic drugs for the treatment of moderate to severe psoriasis, as well as IL-17 and IL-23 drugs in the pipeline, we in the field of psoriasis will have an excellent group of quality bio- logic drugs available to us within the next year.
Psoriasis & Psoriatic Arthritis is a supplement addressing new therapeutic advances and research that will change patient care. “We highlight late-breaking, novel research that will help shape the future of psoriasis therapeutics. Specifically, we discuss psoriasis research that has focused on traditionally overlooked subpopulations,” noted Dr. April W. Armstrong in the supplement’s introduction. Dr. Alan Menter added, “With the introduction of new interleukin (IL)-17 as well as IL-23 biologic drugs for the treatment of moderate to severe psoriasis, as well as IL-17 and IL-23 drugs in the pipeline, we in the field of psoriasis will have an excellent group of quality bio- logic drugs available to us within the next year.
CME: Current Trends in Multiple Myeloma: Customizing Treatment Strategies and Optimizing Outcomes
Click here to read the digital edition of the supplement
This supplement is supported by an educational education grant from Celgene and Janssen Biotech, Inc.
Topics Include:
- Advances in diagnosis and prognosis
- Management of the newly diagnosed patient
- Treatment advances and current management strategies for relapsed/refractory patients
- Future treatment directions
About the Author
Thomas R. Chauncey, MD, PhD
Associate Professor of Medicine and Oncology
University of Washington
Associate Member
Fred Hutchinson Cancer Research Center
Director, Marrow Transplant Unit
VA Puget Sound Health Care System
Seattle, WA
Click here to read the digital edition of the supplement
Click here to read the digital edition of the supplement
This supplement is supported by an educational education grant from Celgene and Janssen Biotech, Inc.
Topics Include:
- Advances in diagnosis and prognosis
- Management of the newly diagnosed patient
- Treatment advances and current management strategies for relapsed/refractory patients
- Future treatment directions
About the Author
Thomas R. Chauncey, MD, PhD
Associate Professor of Medicine and Oncology
University of Washington
Associate Member
Fred Hutchinson Cancer Research Center
Director, Marrow Transplant Unit
VA Puget Sound Health Care System
Seattle, WA
Click here to read the digital edition of the supplement
Click here to read the digital edition of the supplement
This supplement is supported by an educational education grant from Celgene and Janssen Biotech, Inc.
Topics Include:
- Advances in diagnosis and prognosis
- Management of the newly diagnosed patient
- Treatment advances and current management strategies for relapsed/refractory patients
- Future treatment directions
About the Author
Thomas R. Chauncey, MD, PhD
Associate Professor of Medicine and Oncology
University of Washington
Associate Member
Fred Hutchinson Cancer Research Center
Director, Marrow Transplant Unit
VA Puget Sound Health Care System
Seattle, WA
Click here to read the digital edition of the supplement
Recommendations to Improve Asthma Outcomes: Work Group Call to Action
Click here to read the supplement.
What can be done to address the burden of asthma beyond pharmacotherapy? A panel of experts discuss steps for addressing sensitization to allergens that trigger increased asthma burden.
Topics Include:
- Identifying Patients with Allergic Components of Asthma
- Identifying and Addressing Allergen Exposure in Daily Practice
- The Opportunity for Payers and Health Systems for Supporting Trigger Avoidance Education
Click here to read the supplement.
Click here to read the supplement.
What can be done to address the burden of asthma beyond pharmacotherapy? A panel of experts discuss steps for addressing sensitization to allergens that trigger increased asthma burden.
Topics Include:
- Identifying Patients with Allergic Components of Asthma
- Identifying and Addressing Allergen Exposure in Daily Practice
- The Opportunity for Payers and Health Systems for Supporting Trigger Avoidance Education
Click here to read the supplement.
Click here to read the supplement.
What can be done to address the burden of asthma beyond pharmacotherapy? A panel of experts discuss steps for addressing sensitization to allergens that trigger increased asthma burden.
Topics Include:
- Identifying Patients with Allergic Components of Asthma
- Identifying and Addressing Allergen Exposure in Daily Practice
- The Opportunity for Payers and Health Systems for Supporting Trigger Avoidance Education
Click here to read the supplement.
Recommendations to Improve Asthma Outcomes: Work Group Call to Action
Click here to read the supplement.
What can be done to address the burden of asthma beyond pharmacotherapy? A panel of experts discuss steps for addressing sensitization to allergens that trigger increased asthma burden.
Topics Include:
- Identifying Patients with Allergic Components of Asthma
- Identifying and Addressing Allergen Exposure in Daily Practice
- The Opportunity for Payers and Health Systems for Supporting Trigger Avoidance Education
Click here to read the supplement.
Click here to read the supplement.
What can be done to address the burden of asthma beyond pharmacotherapy? A panel of experts discuss steps for addressing sensitization to allergens that trigger increased asthma burden.
Topics Include:
- Identifying Patients with Allergic Components of Asthma
- Identifying and Addressing Allergen Exposure in Daily Practice
- The Opportunity for Payers and Health Systems for Supporting Trigger Avoidance Education
Click here to read the supplement.
Click here to read the supplement.
What can be done to address the burden of asthma beyond pharmacotherapy? A panel of experts discuss steps for addressing sensitization to allergens that trigger increased asthma burden.
Topics Include:
- Identifying Patients with Allergic Components of Asthma
- Identifying and Addressing Allergen Exposure in Daily Practice
- The Opportunity for Payers and Health Systems for Supporting Trigger Avoidance Education
